CoChat

Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets

Open access

The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.

Abstract

Dedifferentiated liposarcoma (DDLS) is a rare but aggressive cancer with high recurrence and low response rates to targeted therapies. Increasing treatment efficacy may require combinations of targeted agents that counteract the effects of multiple abnormalities. To identify a possible multicomponent therapy, we performed a combinatorial drug screen in a DDLS-derived cell line and identified cyclin-dependent kinase 4 (CDK4) and insulin-like growth factor 1 receptor (IGF1R) as synergistic drug targets. We measured the phosphorylation of multiple proteins and cell viability in response to systematic drug combinations and derived computational models of the signaling network. These models predict that the observed synergy in reducing cell viability with CDK4 and IGF1R inhibitors depends on the activity of the AKT pathway. Experiments confirmed that combined inhibition of CDK4 and IGF1R cooperatively suppresses the activation of proteins within the AKT pathway. Consistent with these findings, synergistic reductions in cell viability were also found when combining CDK4 inhibition with inhibition of either AKT or epidermal growth factor receptor (EGFR), another receptor similar to IGF1R that activates AKT. Thus, network models derived from context-specific proteomic measurements of systematically perturbed cancer cells may reveal cancer-specific signaling mechanisms and aid in the design of effective combination therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scisignal.2004014

Cites

97 of 97 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 97 references

Cited by

Metadata

Authors
Miller, M. L., Molinelli, E. J., Nair, J. S., Sheikh, T., Samy, R., Jing, X., He, Q., Korkut, A., Crago, A. M., Singer, S., Schwartz, G. K., & Sander, C.
Affiliations
Memorial Sloan Kettering Cancer Center (US)
Corresponding author
  • Miller, Martin L.
  • Molinelli, Evan J.
  • Singer, Samuel
  • Schwartz, Gary K.
  • Sander, Chris
Venue
Science Signaling
Published
2013-09-24
Volume
6
Issue
294
Pages
ra85-ra85
ISSN
  • 1937-9145 (ISSN-L)
  • 1945-0877
OpenAlex
W2129662907
Cited by
86
References
97
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 9 · 2022: 5 · 2021: 5 · 2020: 7 · 2019: 6 · 2018: 11 · 2017: 9 · 2016: 6 · 2015: 12 · 2014: 9 · 2013: 2
FWCI
7.87
Type
journal article
Language
en
Open access
Locations
  • Science Signaling (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (5t32gm083937-09)
  • National Cancer Institute (U54CA148967, P50CA140146, U54CA143798, P30CA008748)
  • National Institute of General Medical Sciences (1T32GM083937, GM 103504, T32-GM083937, P41GM103504)
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords
dedifferentiated liposarcoma, CDK4, IGF-1 receptor, drug synergy, combination therapy, Akt signaling, EGFR, signaling network modeling, protein phosphorylation, cell viability, targeted therapy
MeSH terms
Antineoplastic Combined Chemotherapy Protocols, Computer Simulation, Drug Screening Assays, Antitumor, Drug Synergism, Humans, Liposarcoma, Models, Biological, Signal Transduction, Drug Delivery Systems, Receptor, IGF Type 1, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, Cyclin-Dependent Kinase 4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.